Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The inspection concluded with zero form 483 observations
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Merck opens first climate-neutral manufacturing facility in Ireland
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
Subscribe To Our Newsletter & Stay Updated
